Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Astrocytoma × Valacyclovir × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Lung Neoplasms 1 Glioma 1 Glioblastoma 1 Epstein-Barr Virus Infections 1 Cytomegalovirus Infections 1 Carcinoma, Non-Small-Cell Lung 1 Astrocytoma 1

Interventions

Temozolomide 27 Bevacizumab 14 Radiotherapy 12 antineoplaston AS 2-1 8 antineoplaston A10 8 Erlotinib Hydrochloride 6 Radiation 5 Everolimus 5 Radiotherapy, Intensity-Modulated 4 palbociclib 3 Vorinostat 3 Sunitinib 3 Lomustine 3 Carmustine 3 Carboplatin 3 selinexor 2 poly ICLC 2 etoposide phosphate 2 cabozantinib 2 Radiotherapy, Conformal 2 Nivolumab 2 Magnetic Resonance Spectroscopy 2 Irinotecan 2 Immunoglobulin G 2 Donepezil 2 Disulfides 2 Dasatinib 2 Corticotropin-Releasing Hormone 2 Cancer Vaccines 2 Adjuvants, Immunologic 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00589875 2024-04-03

BrTK02

Candel Therapeutics, Inc.

Phase 2 Completed

52 enrolled 10 charts

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡